Sugi Predict

Sugi Predict / Compounds / SCHEMBL3517355

SCHEMBL3517355

SCHEMBL3517355

FC(F)(F)c1ccnnc1Cl

nearest known ligand 0.35

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 9/20 0.35
▸ XPO1 O14980 3/20 0.34
▸ ADRB2 P07550 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ RPS6KA5 O75582 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ HSD11B1 P28845 1/20 0.32
▸ NPC1 O15118 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ P2RX7 Q99572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30851943 1.00 NOTUM (0.35) NOTUMXPO1ADRB2L3MBTL1RPS6KA5
SCHEMBL34471572 0.81 NOTUM (0.33) NOTUML3MBTL1HSD11B1
SCHEMBL28787398 0.79 CYP3A4 (0.33) —
SCHEMBL21100791 0.77 CA2 (0.30) —
SCHEMBL34472456 0.77 L3MBTL1 (0.46) L3MBTL1NPC1POLBP2RX7
SCHEMBL3516550 0.73 GLA (0.40) NOTUMPOLB
SCHEMBL22585349 0.73 NOTUM (0.32) NOTUM
SCHEMBL669116 0.73 NOTUM (0.32) NOTUM
SCHEMBL17103409 0.73 NOTUM (0.32) NOTUM
SCHEMBL16276908 0.73 HSD11B1 (0.37) NOTUMHSD11B1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230172-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2025-07-17 — — US disclosed
EP-4559908-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF S2CBio Inc. (KR) 2025-05-28 — — EP disclosed
WO-2024217500-A1 ISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海赛默罗生物科技有限公司 2024-10-24 — — WO disclosed
EP-4416152-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-08-21 — — EP disclosed
WO-2024059096-A2 C5AR1 ANTAGONISTS AND USES THEREOF VANQUA BIO, INC. (US) 2024-03-21 — — WO disclosed
WO-2024058617-A1 ANTIVIRAL USE OF HETEROARYL DERIVATIVE COMPOUND 일동제약(주) 2024-03-21 — — WO disclosed
WO-2024019541-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 일동제약(주) 2024-01-25 — — WO disclosed
WO-2023064345-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2023-04-20 — — WO disclosed
US-10675268-B2 Somatostatin receptor subtype 4 (SSTR4) agonists CENTREXION THERAPEUTICS CORPORATION (US) 2020-06-09 — — US disclosed
US-20190269650-A1 NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2019-09-05 — — US disclosed
EP-1841430-A4 SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORP (US) 2009-07-29 — — EP disclosed
WO-2009086130-A1 IMIDAZO [1,2-B] PYRIDAZINE COMPOUNDS AS MODULATORS OF LIVER X RECEPTORS WYETH (US) 2009-07-09 — — WO disclosed
WO-2009086130-A1 IMIDAZO [1,2-B] PYRIDAZINE COMPOUNDS AS MODULATORS OF LIVER X RECEPTORS WYETH (US) 2009-07-09 — — WO disclosed
CN-101232885-A Substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogues NEUROGEN CORP (US) 2008-07-30 — — CN disclosed
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues NEUROGEN CORPORATION (US) 2008-07-24 — — US disclosed
EP-1841430-A2 SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2007-10-10 — — EP disclosed
WO-2006081388-A2 SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2006-08-03 — — WO disclosed
US-20060154930-A1 Substituted amino heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-07-13 — — US disclosed
EP-1597261-A1 SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-11-23 — — EP disclosed
WO-2004074290-A1 SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-09-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154930-A1 Substituted amino heterocycles as vr-1 antagonists for treating pain OPRL1, OPRM1, OPRK1 NOTUM 4773/4885XPO1 1177/4885ADRB2 30/4885
US-20190269650-A1 NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS SSTR4, SSTR3, SSTR1 NOTUM 3801/4885XPO1 4234/4885ADRB2 229/4885
US-10675268-B2 Somatostatin receptor subtype 4 (SSTR4) agonists SSTR4, SSTR3, SSTR1 NOTUM 4066/4885XPO1 4384/4885ADRB2 236/4885
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues PIGS, HRH4, GPR68 NOTUM 4316/4885XPO1 4394/4885ADRB2 171/4885
US-20250230172-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 NOTUM 1739/4885XPO1 3508/4885ADRB2 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.